Shifamed

Shifamed is a medical technology innovation hub based in Campbell, California, in the heart of Silicon Valley. The company describes itself as a purpose-driven group of entrepreneurs, innovators, and engineers focused on building next-generation medical products that improve clinical standards and patients' lives. Its name is derived from the Arabic and Hebrew root "shifa" (to heal or to cure) and the Latin "med" (from mederi, to heal), reflecting its healthcare mission. Since 2007, Shifamed has worked to accelerate the future of medical devices by bringing together thinkers and makers from both inside and outside the medtech industry. The firm operates through a structured process of insight, strategy, ideation, and results, using a rigorous idea evaluation process to focus on critical unmet clinical needs. Its structure, resources, and processes are designed to help teams rapidly turn promising projects into breakthrough medical technology. Shifamed's model is to found and incubate medical device companies, develop their products, and realize value through both direct development and strategic acquisition. Its portfolio companies have addressed areas such as atrial fibrillation ablation, intravascular filtration, electrophysiology catheters, renal denervation, intracardiac imaging, and percutaneous aortic valve replacement. Several portfolio companies have been acquired by major medical device firms, including Boston Scientific, Abbott, Covidien, and Johnson & Johnson. The company is privately held and operates from a state-of-the-art campus in Silicon Valley. It continues to work on several companies in various phases of development, from stealth mode and early-stage design to commercial release and next-generation work.

Shifamed was founded in 2007 and is headquartered in Campbell, California, in Silicon Valley. The company was established as a medical technology innovation hub with a mission to accelerate the development of next-generation medical devices. Its name combines "shifa," an Arabic and Hebrew word meaning to heal or to cure, and "med," from the Latin mederi, to heal. From its early years, Shifamed pursued a model of founding and incubating medical device companies rather than operating as a single-product developer. It brought together entrepreneurs, engineers, and clinicians to identify unmet clinical needs and develop technologies to address them. The company's process emphasizes insight, strategy, ideation, and results, with a rigorous evaluation of ideas to focus resources on the most critical clinical challenges. Over time, Shifamed built a portfolio of companies in diverse areas of medical technology. One of its earliest successes was Embolic Protection, Inc. (EPI), an intravascular filter company that was sold to Boston Scientific in 2001 for $75 million in cash up-front, with an undisclosed amount in milestone payments. This was followed by Maya Medical, a renal denervation company sold to Covidien in 2012 for $60 million in cash up-front, with up to $170 million in milestone payments. In 2016, Kalila Medical, which provides catheters for complex electrophysiology procedures and vascular interventions, was sold to Abbott for an undisclosed amount. In 2017, Apama Medical, an atrial fibrillation ablation company, was sold to Boston Scientific for $175 million in cash up-front, with up to $125 million in milestone payments. In 2020, NuVera Medical, an advanced real-time intracardiac imaging (4D ICE) company, was sold to Johnson & Johnson for an undisclosed amount. Sadra Medical, a percutaneous aortic valve replacement company, was also part of the legacy portfolio. These exits demonstrated Shifamed's ability to create value through strategic acquisitions and provided returns for investors. The company has continued to work on several companies in various phases of development, from stealth mode and early-stage design to commercial release and next-generation work. It operates from a state-of-the-art campus in Silicon Valley and remains privately held.

• 2020

  NuVera Medical sold to Johnson & Johnson for an undisclosed amount.

• 2017

  Apama Medical sold to Boston Scientific for $175 million in cash up-front plus up to $125 million in milestones.

• 2016

  Kalila Medical sold to Abbott for an undisclosed amount.

• 2012

  Maya Medical sold to Covidien for $60 million in cash up-front plus up to $170 million in milestones.

• 2007

  Shifamed founded as a medical technology innovation hub.

• 2001

  Embolic Protection, Inc. (EPI) sold to Boston Scientific for $75 million in cash up-front plus undisclosed milestones.

A highly specialized medical technology innovation hub that founds and develops medical device companies, bringing products to market through direct development and strategic acquisition.

• Apama Medical

  Atrial fibrillation ablation company, sold to Boston Scientific in 2017.

• Embolic Protection, Inc. (EPI)

  Intravascular filter company, sold to Boston Scientific in 2001.

• Kalila Medical

  Catheter company for electrophysiology and vascular interventions, sold to Abbott in 2016.

• Maya Medical

  Renal denervation company, sold to Covidien in 2012.

• NuVera Medical

  Advanced real-time intracardiac imaging (4D ICE) company, sold to Johnson & Johnson in 2020.

• Sadra Medical

  Percutaneous aortic valve replacement company, part of legacy portfolio.

1. 1Shifamedshifamed.com
2. 2About | Shifamedshifamed.com
3. 3Portfolio | Shifamedshifamed.com
4. 4Shifamed (United States) - Wikidatawikidata.org